Skip to content

Lifecore Biomedical, Inc. LFCR Reportable Segment — Revenue

Similar metrics at other companies

Aquestive Therapeutics, Inc. logo
AQSTReportable Segment — Revenue
$14.45M+65.7%
Arbutus Biopharma Corporation logo
ABUSReportable Segment — Revenue
$179.13M+10,055%
Consensus Cloud Solutions, Inc. logo
CCSIReportable Segment — Revenue
$88.47M+1.5%
Claritev Corporation logo
CTEVReportable Segment — Revenue
$244.68M+5.8%
Taboola.com Ltd. logo
TBLAReportable Segment — Revenue
$466.4M+9.1%
Lexicon Pharmaceuticals logo
LXRXReportable Segment — Revenue
$21.1M+1,572%

Other financials

Income statement

See full
Revenue$23.2M-36.4%
Gross profit$4.5M-68.1%
Operating income-$4.7M
Net income-$15.0M-1,206%
EPS (diluted)-$0.43-1,333%

Balance sheet

See full
Cash & equivalents$20.8M+152%
Total debt$156.9M+1,310%
Total equity-$28.4M-2,229%
Total assets$225.5M-5.8%

Cash flow

See full
Operating cash flow$4.7M
CapEx$1.1M-46.7%
Free cash flow$3.6M

Valuation

See full
Market cap$196.92M-35.4%
Enterprise value$333.06M+8.3%
P/S1.6×+0.5×

Profitability

See full
Gross margin31.3%-1.4pp
Operating margin-14.5%-2.2pp
Net margin-30%
FCF margin-36.4%

Returns & leverage

See full
Return on equity-612.1%
Debt / equity8.3×-1.5×
Current ratio3.8×+0.9×

Where this comes from

Reported directly by Lifecore Biomedical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.

The official record: Lifecore Biomedical, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lifecore Biomedical, Inc.'s reportable segment — revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lifecore Biomedical, Inc.'s reportable segment — revenue?
Lifecore Biomedical, Inc. (LFCR) reported reportable segment — revenue of $23.19M in Q1 2026.
What does reportable segment — revenue mean?
This metric represents the total gross income generated by the business segment from its primary operating activities, including contract development, manufacturing, and fermentation services. It serves as a key indicator of the segment's market demand and top-line growth potential within the sterile injectable pharmaceutical industry.